Is Bluejay Diagnostics Stock a Good Investment?
Bluejay Diagnostics Investment Advice | BJDX |
- Examine Bluejay Diagnostics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Bluejay Diagnostics' leadership team and their track record. Good management can help Bluejay Diagnostics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Bluejay Diagnostics' business and its evolving consumer preferences.
- Compare Bluejay Diagnostics' performance and market position to its competitors. Analyze how Bluejay Diagnostics is positioned in terms of product offerings, innovation, and market share.
- Check if Bluejay Diagnostics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Bluejay Diagnostics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Bluejay Diagnostics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Bluejay Diagnostics is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Insignificant | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Bluejay Diagnostics Stock
Researching Bluejay Diagnostics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book (P/B) ratio of 0.32. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bluejay Diagnostics recorded a loss per share of 804.0. The entity had not issued any dividends in recent years. The firm had 1:50 split on the 18th of November 2024.
To determine if Bluejay Diagnostics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bluejay Diagnostics' research are outlined below:
| Bluejay Diagnostics had very high historical volatility over the last 90 days | |
| Bluejay Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (9.95 M) with profit before overhead, payroll, taxes, and interest of 48.91 K. | |
| Bluejay Diagnostics currently holds about 15.34 M in cash with (8.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Bluejay Diagnostics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: 12 Health Care Stocks Moving In Thursdays After-Market Session - Benzinga India |
Bluejay Diagnostics Quarterly Liabilities And Stockholders Equity |
|
Bluejay Diagnostics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bluejay Diagnostics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bluejay Diagnostics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 18th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Bluejay Diagnostics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Bluejay Diagnostics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-07-26 | 2022-06-30 | -0.08 | -0.1 | -0.02 | 25 | ||
2023-05-10 | 2023-03-31 | -0.06 | -0.12 | -0.06 | 100 | ||
2022-11-08 | 2022-09-30 | -0.08 | -0.15 | -0.07 | 87 | ||
2023-03-20 | 2022-12-31 | 0.04 | -0.12 | -0.16 | 400 | ||
2024-03-28 | 2023-12-31 | -0.68 | -1.86 | -1.18 | 173 | ||
2023-08-14 | 2023-06-30 | -1.5 | -2.75 | -1.25 | 83 | ||
2023-11-09 | 2023-09-30 | -0.81 | -2.08 | -1.27 | 156 |
Know Bluejay Diagnostics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bluejay Diagnostics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bluejay Diagnostics backward and forwards among themselves. Bluejay Diagnostics' institutional investor refers to the entity that pools money to purchase Bluejay Diagnostics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Investments Llc | 2024-12-31 | 0.0 | Virtu Financial Llc | 2024-09-30 | 0.0 | Two Sigma Securities, Llc | 2024-12-31 | 0.0 | Hrt Financial Llc | 2024-12-31 | 0.0 | Ubs Group Ag | 2024-12-31 | 1.9 K | Tower Research Capital Llc | 2024-12-31 | 554 | Bank Of America Corp | 2024-12-31 | 4.0 | Advisor Group Holdings, Inc. | 2024-09-30 | 3.0 | Sabby Management Llc | 2024-12-31 | 0.0 | Warberg Asset Management Llc | 2024-09-30 | 0.0 | Citadel Advisors Llc | 2024-12-31 | 0.0 |
Bluejay Diagnostics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.17 M.Market Cap |
|
Bluejay Diagnostics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.35) | (2.23) | |
| Return On Capital Employed | (3.83) | (3.64) | |
| Return On Assets | (2.35) | (2.23) | |
| Return On Equity | (3.95) | (3.76) |
Determining Bluejay Diagnostics' profitability involves analyzing its financial statements and using various financial metrics to determine if Bluejay Diagnostics is a good buy. For example, gross profit margin measures Bluejay Diagnostics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bluejay Diagnostics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Bluejay Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bluejay Diagnostics. Check Bluejay Diagnostics' Beneish M Score to see the likelihood of Bluejay Diagnostics' management manipulating its earnings.
Evaluate Bluejay Diagnostics' management efficiency
Bluejay Diagnostics has return on total asset (ROA) of (0.6078) % which means that it has lost $0.6078 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3878) %, meaning that it created substantial loss on money invested by shareholders. Bluejay Diagnostics' management efficiency ratios could be used to measure how well Bluejay Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -2.23 in 2025. Return On Capital Employed is likely to rise to -3.64 in 2025. At this time, Bluejay Diagnostics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 34.6 K in 2025, whereas Net Tangible Assets are likely to drop slightly above 6.8 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 19.01 | 29.58 | |
| Tangible Book Value Per Share | 19.01 | 29.55 | |
| Enterprise Value Over EBITDA | (6.38) | (6.70) | |
| Price Book Value Ratio | 20.79 | 21.83 | |
| Enterprise Value Multiple | (6.38) | (6.70) | |
| Price Fair Value | 20.79 | 21.83 | |
| Enterprise Value | 336 M | 298.7 M |
Management at Bluejay Diagnostics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Beta 0.377 |
Basic technical analysis of Bluejay Stock
As of the 24th of March, Bluejay Diagnostics shows the Mean Deviation of 5.38, standard deviation of 7.16, and Risk Adjusted Performance of (0.01). Bluejay Diagnostics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Bluejay Diagnostics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bluejay Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bluejay Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bluejay Diagnostics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bluejay Diagnostics' Outstanding Corporate Bonds
Bluejay Diagnostics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bluejay Diagnostics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bluejay bonds can be classified according to their maturity, which is the date when Bluejay Diagnostics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Bluejay Diagnostics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Bluejay Diagnostics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 5.38 | |||
| Coefficient Of Variation | (6,369) | |||
| Standard Deviation | 7.16 | |||
| Variance | 51.23 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.09) | |||
| Total Risk Alpha | 0.1671 | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 42.86 | |||
| Value At Risk | (12.22) | |||
| Potential Upside | 10.59 | |||
| Skewness | 0.5418 | |||
| Kurtosis | 2.12 |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 5.38 | |||
| Coefficient Of Variation | (6,369) | |||
| Standard Deviation | 7.16 | |||
| Variance | 51.23 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.09) | |||
| Total Risk Alpha | 0.1671 | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 42.86 | |||
| Value At Risk | (12.22) | |||
| Potential Upside | 10.59 | |||
| Skewness | 0.5418 | |||
| Kurtosis | 2.12 |
Consider Bluejay Diagnostics' intraday indicators
Bluejay Diagnostics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bluejay Diagnostics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 6847.9 | |||
| Daily Balance Of Power | (0.67) | |||
| Rate Of Daily Change | 0.94 | |||
| Day Median Price | 4.0 | |||
| Day Typical Price | 3.97 | |||
| Price Action Indicator | (0.20) | |||
| Period Momentum Indicator | (0.26) |
Bluejay Diagnostics Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
8K | 4th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Bluejay Stock media impact
Far too much social signal, news, headlines, and media speculation about Bluejay Diagnostics that are available to investors today. That information is available publicly through Bluejay media outlets and privately through word of mouth or via Bluejay internal channels. However, regardless of the origin, that massive amount of Bluejay data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Bluejay Diagnostics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Bluejay Diagnostics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Bluejay Diagnostics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Bluejay Diagnostics alpha.
Bluejay Diagnostics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Bluejay Diagnostics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Bluejay Diagnostics Corporate Management
| Kenneth CPA | Chief Officer | Profile | |
| Kevin Vance | Chief Officer | Profile | |
| Jason Cook | Chief Officer | Profile | |
| Mark MD | Chief Advisor | Profile | |
| Les DeLuca | Vice Operations | Profile | |
| Eryn Graham | Marketing Manager | Profile |
Additional Tools for Bluejay Stock Analysis
When running Bluejay Diagnostics' price analysis, check to measure Bluejay Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluejay Diagnostics is operating at the current time. Most of Bluejay Diagnostics' value examination focuses on studying past and present price action to predict the probability of Bluejay Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluejay Diagnostics' price. Additionally, you may evaluate how the addition of Bluejay Diagnostics to your portfolios can decrease your overall portfolio volatility.